Martin Erlanson
- Pathology and Forensic Medicine top 0.5%
- Oncology top 2%
- Immunology top 5%
- Genetics top 2%
- Molecular Biology
- Co-authors
- Hans HagbergGöran RoosGunilla EnbladChrister SundströmGöran LandbergBjørn ØstenstadBarbro LinderholmHarald Holte
- Topics
- Lymphoma Diagnosis and Treatment (46 papers)Chronic Lymphocytic Leukemia Research (15 papers)Viral-associated cancers and disorders (13 papers)
In The Last Decade
Martin Erlanson
67 papers receiving 2.3k citations
Peers
Comparison fields: 5 of 86
- Pathology and Forensic Medicine 1.4k
- Oncology 1.2k
- Immunology 543
- Genetics 499
- Molecular Biology 415
Countries citing papers authored by Martin Erlanson
This map shows the geographic impact of Martin Erlanson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Erlanson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Erlanson more than expected).
Fields of papers citing papers by Martin Erlanson
This network shows the impact of papers produced by Martin Erlanson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Erlanson. The network helps show where Martin Erlanson may publish in the future.
Co-authorship network of co-authors of Martin Erlanson
This figure shows the co-authorship network connecting the top 25 collaborators of Martin Erlanson. A scholar is included among the top collaborators of Martin Erlanson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Erlanson. Martin Erlanson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 18 | |
| 3 | A HIGHER AMOUNT OF LILOTOMAB PRE-DOSING INCREASES THE ACTIVITY-ADJUSTED AUC AND HAS A PROTECTIVE EFFECT AGAINST MYELOSUPPRESSION OF LUTETIUM (177LU)-LILOTOMAB SATETRAXETAN IN INDOLENT NHL PATIENTS | 1 |
| 4 | 79 | |
| 5 | 95 | |
| 6 | 386 | |
| 7 | 86 | |
| 8 | Upfront Autologuos Stem Cell Transplantation in Peripheral T-cell Lymphoma (NLG-T-01) | 1 |
| 9 | 41 | |
| 10 | Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral t-cell lymphomas (PTCLS) - overall and subtype-specific results of a phase II study from the nordic lymphoma group | 20 |
| 11 | 16 | |
| 12 | 41 | |
| 13 | 11 | |
| 14 | 1 | |
| 15 | 10 | |
| 16 | 56 | |
| 17 | 97 | |
| 18 | 16 | |
| 19 | 2 | |
| 20 | 35 |
About Martin Erlanson
Martin Erlanson is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology, having authored 67 papers that have together received 2.3k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (46 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Viral-associated cancers and disorders (13 papers). The work is most often cited by research in Pathology and Forensic Medicine (1.4k citations), Genetics (499 citations) and Oncology (1.2k citations). Martin Erlanson has collaborated with scholars based in Sweden, Norway and Denmark. Frequent co-authors include Hans Hagberg, Göran Roos, Gunilla Enblad, Christer Sundström, Göran Landberg, Bjørn Østenstad, Barbro Linderholm, Harald Holte, Jack Lindh and Outi Kuittinen. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.